Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114


ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.

Wilzén A, Krona C, Sveinbjörnsson B, Kristiansson E, Dalevi D, Øra I, De Preter K, Stallings RL, Maris J, Versteeg R, Nilsson S, Kogner P, Abel F.

Mol Cancer. 2013 Jul 8;12(1):70. doi: 10.1186/1476-4598-12-70.


Cyclin D1 in pediatric neuroblastic tumors: A microarray analysis.

Fagone P, Nicoletti F, Vecchio GM, Parenti R, Magro G.

Acta Histochem. 2015 Oct;117(8):820-3. doi: 10.1016/j.acthis.2015.10.002. Epub 2015 Oct 25.


Brain lipid-binding protein: a marker of differentiation in neuroblastic tumors.

Retrosi G, Sebire NJ, Bishay M, Kiely EM, Anderson J, De Coppi P, Resca E, Rampling D, Bier N, Mills K, Eaton S, Pierro A.

J Pediatr Surg. 2011 Jun;46(6):1197-200. doi: 10.1016/j.jpedsurg.2011.03.053.


Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.

Veschi V, Petroni M, Bartolazzi A, Altavista P, Dominici C, Capalbo C, Boldrini R, Castellano A, McDowell HP, Pizer B, Frati L, Screpanti I, Gulino A, Giannini G.

Cell Death Dis. 2014 Mar 6;5:e1100. doi: 10.1038/cddis.2014.68.


International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S, Gerbing RB, Stram DO, Lukens JN, Matthay KK.

Cancer. 2001 Nov 1;92(9):2451-61.


[Clinicopathologic features of peripheral neuroblastic tumors].

Yang BF, Fu LB, He LJ.

Zhonghua Bing Li Xue Za Zhi. 2013 May;42(5):305-10. doi: 10.3760/cma.j.issn.0529-5807.2013.05.004. Chinese.


Differential expression of delta-like gene and protein in neuroblastoma, ganglioneuroblastoma and ganglioneuroma.

Hsiao CC, Huang CC, Sheen JM, Tai MH, Chen CM, Huang LL, Chuang JH.

Mod Pathol. 2005 May;18(5):656-62.


Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data.

Tabyaoui I, Tahiri-Jouti N, Serhier Z, Bennani-Othmani M, Sibai H, Itri M, Benchekroun S, Zamiati S.

Diagn Pathol. 2013 Feb 27;8:39. doi: 10.1186/1746-1596-8-39.


Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.

Schaefer KL, Brachwitz K, Wai DH, Braun Y, Diallo R, Korsching E, Eisenacher M, Voss R, Van Valen F, Baer C, Selle B, Spahn L, Liao SK, Lee KA, Hogendoorn PC, Reifenberger G, Gabbert HE, Poremba C.

Cancer Res. 2004 May 15;64(10):3395-405.


[Pathology of peripheral neuroblastic tumors].

Wang L, He LJ, Shimada H.

Zhonghua Bing Li Xue Za Zhi. 2012 Apr;41(4):283-8. doi: 10.3760/cma.j.issn.0529-5807.2012.04.020. Chinese. No abstract available.


Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H.

Cancer. 2001 Nov 15;92(10):2699-708.


Role of diffusion-weighted imaging in distinguishing thoracoabdominal neuroblastic tumours of various histological types and differentiation grades.

Wen Y, Peng Y, Duan XM, Zhang N.

J Med Imaging Radiat Oncol. 2017 May 16. doi: 10.1111/1754-9485.12615. [Epub ahead of print]


Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3.

Young CD, Nolte EC, Lewis A, Serkova NJ, Anderson SM.

Breast Cancer Res. 2008;10(4):R70. doi: 10.1186/bcr2132. Epub 2008 Aug 13.


Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN.

Koppen A, Ait-Aissa R, Koster J, Øra I, Bras J, van Sluis PG, Caron H, Versteeg R, Valentijn LJ.

Int J Cancer. 2008 Apr 1;122(7):1455-64.


Enteric neural crest differentiation in ganglioneuromas implicates Hedgehog signaling in peripheral neuroblastic tumor pathogenesis.

Gershon TR, Shiraz A, Qin LX, Gerald WL, Kenney AM, Cheung NK.

PLoS One. 2009 Oct 16;4(10):e7491. doi: 10.1371/journal.pone.0007491. Erratum in: PLoS One. 2014 Jul 25;9(7):e103881. Shirazi, Arash [corrected to Shiraz, Ashton].


Conventional versus modified morphologic criteria for ganglioneuroblastoma. A review of cases from the Pediatric Oncology Group.

Joshi VV, Cantor AB, Altshuler G, Cohen LJ, Larkin EW, Shuster JJ, Rao PV, Holbrook CT, Hayes FA, Castleberry RP.

Arch Pathol Lab Med. 1996 Sep;120(9):859-65.


The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells in vivo.

Schulte JH, Pentek F, Hartmann W, Schramm A, Friedrichs N, Øra I, Koster J, Versteeg R, Kirfel J, Buettner R, Eggert A.

Int J Cancer. 2009 May 15;124(10):2488-94. doi: 10.1002/ijc.24204.


Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status.

Giannini G, Kim CJ, Di Marcotullio L, Manfioletti G, Cardinali B, Cerignoli F, Ristori E, Zani M, Frati L, Screpanti I, Guilino A.

Br J Cancer. 2000 Dec;83(11):1503-9.


GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours.

Ramani P, Headford A, May MT.

Virchows Arch. 2013 Feb;462(2):203-9. doi: 10.1007/s00428-012-1370-4. Epub 2013 Jan 10.


Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells.

Coco S, Defferrari R, Scaruffi P, Cavazzana A, Di Cristofano C, Longo L, Mazzocco K, Perri P, Gambini C, Moretti S, Bonassi S, Tonini GP.

J Pathol. 2005 Nov;207(3):346-57.


Supplemental Content

Support Center